Exagen reported a quarterly loss of $0.20 per share, exactly in line with the Zacks consensus and unchanged from a $0.20 loss a year ago. The result is a flat year-over-year EPS performance with no beat/miss or guidance disclosed, implying limited new information for investors.
Exagen reported a quarterly loss of $0.20 per share, exactly in line with the Zacks consensus and unchanged from a $0.20 loss a year ago. The result is a flat year-over-year EPS performance with no beat/miss or guidance disclosed, implying limited new information for investors.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
